Top

Published in:

01-04-2010 | Research Article

Dual Tracer ¹¹C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment

Authors: José A. Richter, Macarena Rodríguez, Jorge Rioja, Iván Peñuelas, Josep Martí-Climent, Puy Garrastachu, Gemma Quincoces, Javier Zudaire, María J. García-Velloso

Published in: Molecular Imaging and Biology | Issue 2/2010

Abstract

Purpose

The purpose of this study was to evaluate a dual tracer 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) and ¹¹C-choline positron emission tomography (PET) protocol in the detection of biochemical prostate cancer relapse.

Procedures

Seventy-three patients (median Prostate Specific Antigen (PSA) Test value 2.7 ng/ml (1.1–5.4)) after radical treatment. PET scans were performed by means of a ECAT-Exact HR+ in the first 18 patients and in a PET/computed tomography Biograph II in the remaining 55 patients.

Results

The sensitivity of ¹¹C-choline and FDG was 60.6% and 31%. In PSA levels over 1.9 ng/ml, sensitivity increased to 80% and 40%, respectively. In the group receiving adjuvant hormone therapy, the diagnostic yields were 71.2% and 43%, respectively. While ¹¹C-choline-PET could not differentiate well and poorly differentiated Gleason score patients, FDG-PET results were almost significant (p = 0.058).

Conclusions

A PSA value higher than 1.9 ng/ml determines a significant increase in the diagnostic yield. Adjuvant hormonotherapy has no influence on the PET results. FDG has a better correlation with the Gleason score than ¹¹C-choline.

Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270(8):948–954CrossRefPubMed

Moul JW (1998) Treatments options for prostate cancer: part1-stage, grade, PSA and changes in the 1990s. Am J Manag Care 4:1031

Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17(3):127–129PubMed

Consensus statement: guidelines for PSA following radiation therapy (1997) American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041

Partin AW, Pearson JD, Landis PK et al (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649–659CrossRefPubMed

Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6):1632–1642CrossRefPubMed

Coakley FV, Teh HS, Qayyum A, Swanson MG et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233(2):441–448CrossRefPubMed

Sanz G, Robles JE, Gimenez M et al (1999) Positron emission tomography with ¹⁸fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84(9):1028–1031CrossRefPubMed

Jeong HJ, Min JJ, Park JM et al (2002) Determination of the prognostic value of [(18) F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23(9):865–870CrossRefPubMed

10.

Nunez R, Macapinlac HA, Yeung HW et al (2002) Combined 18F-FDG and ¹¹C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46–55PubMed

11.

Oyama N, Miller TR, Dehdashti F et al (2003) ¹¹C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44(4):549–555PubMed

12.

Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39(6):990–995PubMed

13.

Breeuwsma AJ, Pruim J, Jongen MM et al (2005) In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 32(6):668–673CrossRefPubMed

14.

Van Laere K, Ceyssens S, Van Calenbergh F et al (2005) Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32(1):39–51CrossRefPubMed

15.

Richter JA, Rodriguez M, Martinez Monge R et al (2005) Value of PET18FDG and 11C-choline in the early diagnosis of relapse in prostate cancer. J Nucl Med 46:98P [abstract]

16.

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597CrossRefPubMed

17.

Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T et al (2004) Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 58:382–390CrossRefPubMed

18.

Moul JW (2003) Biochemical recurrence of prostate cancer. Curr Probl Cancer 27(5):243–272CrossRefPubMed

19.

Peñuelas I, Martí-Climent JM, García-Velloso MJ, Rodríguez-Fraile M, Richter JA (2003) Automatización de la síntesis en fase sólida y la purificación de (N-metil[11C])colina. Rev Esp Med Nuclear 22(3):163 [abstract]

20.

Picchio M, Messa C, Landoni C et al (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169(4):1337–1340CrossRefPubMed

21.

de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44(1):32–38CrossRefPubMed

22.

Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [(11) C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18–23CrossRefPubMed

23.

Reske SN, Blumstein NM, Glatting G (2008) [(11) C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35(1):9–17CrossRefPubMed

24.

Rinnab L, Mottaghy FM, Blumstein NM et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786–793CrossRefPubMed

25.

Husarik DB, Miralbell R, Dubs M, John H et al (2008) Evaluation of [(18) F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253–263CrossRefPubMed

26.

Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165(4):1146–1151CrossRefPubMed

27.

Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61(2):365–369CrossRefPubMed

28.

D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95(18):1376–1383PubMed

29.

Vees H, Buchegger F, Albrecht S et al (2007) 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99(6):1415–1420CrossRefPubMed

30.

Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA >5 ng/ml? Mol Imaging Biol 8(1):43–48CrossRefPubMed

31.

Coleman R, DeGrado T, Wang S et al (2000) Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3(4):147 [Abstract]CrossRefPubMed

32.

Kubota K, Kubota R, Yamada S (1993) FDG accumulation in tumor tissue. J Nucl Med 34(3):419–421PubMed

33.

Minn H, Joensuu H, Ahonen A, Klemi P (1988) Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 61(9):1776–1781CrossRefPubMed

34.

Gheiler EL, Tefilli MV, Tiguert R et al (1998) Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51(5):789–795CrossRefPubMed

35.

Pucar D, Sella T, Schöder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18(1):87–97CrossRefPubMed

36.

Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2):432–439PubMed

37.

Albertsen PC, Hanley JA, Harlan LC et al (2000) The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 163(4):1138–1143CrossRefPubMed

38.

Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2):379–385CrossRefPubMed

Title: Dual Tracer 11C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment
Authors: José A. Richter
Macarena Rodríguez
Jorge Rioja
Iván Peñuelas
Josep Martí-Climent
Puy Garrastachu
Gemma Quincoces
Javier Zudaire
María J. García-Velloso
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 2/2010
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-009-0243-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Dual Tracer ¹¹C-Choline and FDG-PET in the Diagnosis of Biochemical Prostate Cancer Relapse After Radical Treatment

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2010

Dynamic Contrast-Enhanced Folate-Receptor-Targeted MR Imaging Using a Gd-loaded PEG-Dendrimer–Folate Conjugate in a Mouse Xenograft Tumor Model

Incremental Value of Integrated FDG-PET/CT in Evaluating Indeterminate Solitary Pulmonary Nodule for Malignancy

Acquisition Parameters for Oncologic Imaging with a New SPECT/Multislice CT Scanner

Additional Value of FDG-PET/CT in Management of “Solitary” Liver Metastases: Preliminary Results of a Prospective Multicenter Study

[11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma

COMT Val158Met Genotype Does Not Alter Cortical or Striatal Dopamine D2 Receptor Availability In Vivo